JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266203

Human PPP1R16A knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

PPP1R16A KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 10 bp deletion in exon 1 and 1 bp deletion in exon 1. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
2 Images
Sanger Sequencing - Human PPP1R16A knockout HEK-293T cell line (AB266203)
  • Sanger seq

Unknown

Sanger Sequencing - Human PPP1R16A knockout HEK-293T cell line (AB266203)

Allele-1 : 10 bp deletion in exon 1

Sanger Sequencing - Human PPP1R16A knockout HEK-293T cell line (AB266203)
  • Sanger seq

Unknown

Sanger Sequencing - Human PPP1R16A knockout HEK-293T cell line (AB266203)

Allele-2 : 1 bp deletion in exon 1.

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 10 bp deletion in exon 1 and 1 bp deletion in exon 1

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266203-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266203 Human PPP1R16A knockout HEK-293T cell line", "number":"AB266203-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266203-CMP02" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266203-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266203-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab266203 Human PPP1R16A knockout HEK-293T cell line", "number":"AB266203-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266203-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266203 Human PPP1R16A knockout HEK-293T cell line", "number":"AB266203-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266203-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266203 Human PPP1R16A knockout HEK-293T cell line", "number":"AB266203-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
PPP1R16A
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The PPP1R16A protein also known as myosin light chain phosphatase target subunit 1 is part of the protein phosphatase 1 regulatory subunits. It weighs approximately 84 kDa and is mainly found in tissues like brain and skeletal muscle. It functions as a regulatory subunit modulating the activity of protein phosphatase 1 (PP1) a critical enzyme in cellular signaling.
Biological function summary

This protein plays a significant role in the regulation of myosin phosphatase activity influencing muscle function. As part of a multi-subunit complex PPP1R16A interacts with PP1 to dephosphorylate myosin light chains which is essential for muscle relaxation. This process ensures proper muscle contraction and relaxation cycles in response to cellular signals.

Pathways

Protein phosphatase activity plays key roles in both the smooth muscle contraction and Rho GTPase signaling pathways. PPP1R16A by regulating myosin light chain phosphorylation status interacts with proteins like Rho-associated coiled-coil containing protein kinase (ROCK) within these pathways. This involvement positions PPP1R16A as a vital player in pathways that govern cell motility and muscle contraction.

The dysregulation of PPP1R16A activity is associated with conditions such as hypertension and asthma. Its interaction with ROCK and misregulation in myosin phosphatase activity can contribute to abnormal muscle contractility playing a role in the pathophysiology of these diseases. Understanding this interaction helps in exploring therapeutic targets for related cardiovascular and respiratory disorders.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com